Intradermal carboplatin and ifosfamide extravasation in the mouse

Cancer. 1992 Aug 15;70(4):850-3. doi: 10.1002/1097-0142(19920815)70:4<850::aid-cncr2820700421>3.0.co;2-e.

Abstract

Background: Carboplatin and ifosfamide are new antineoplastic agents with vesicant properties that have not been determined. Vesicant activity was investigated in Balb-c mice by administering carboplatin or ifosfamide intradermally in clinically relevant concentrations.

Methods: Carboplatin concentrations tested were 15, 10, and 1 mg/ml; those of ifosfamide were 50, 20, and 1 mg/ml. Five female mice were tested with each concentration; and five animals were used as controls and received only saline.

Results: Carboplatin concentrations of 15 mg/ml and 10 mg/ml produced mean peak ulcer areas of 10 square millimeters (mm2) and 21 mm2 within 2-3 days of injection, respectively. The 1 mg/ml carboplatin injection was not associated with any ulcer formation. Ifosfamide at 50 mg/ml induced skin ulcerations in four of five mice, with maximal effect (19.6 mm2) by 1-2 days. Lower concentrations of ifosfamide produced no ulcerations. All ulcerative lesions healed completely within 21 days.

Conclusions: These results suggest that extravasation of carboplatin at concentrations of greater than or equal to 10 mg/ml or ifosfamide at concentrations of greater than or equal to 50 mg/ml is likely to cause ulcers in humans.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Carboplatin / administration & dosage
  • Carboplatin / toxicity*
  • Dose-Response Relationship, Drug
  • Extravasation of Diagnostic and Therapeutic Materials
  • Female
  • Ifosfamide / administration & dosage
  • Ifosfamide / toxicity*
  • Injections, Intradermal
  • Mice
  • Mice, Inbred BALB C
  • Skin Ulcer / chemically induced*

Substances

  • Carboplatin
  • Ifosfamide